Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline.
European regulators have accepted Novartis’ filing for a triple combination therapy for asthma known as QVM149, triggering payments to development partners Vectura and Sosei.
Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline.
The UK’s medical research charity LifeArc has received a windfall of nearly $1.3 billion after selling a portion of its royalty interest in Merck & Co’s blockbuster cancer drug Keytruda
The Medicines Company (TMC) has bet the proverbial farm on cholesterol-lowering candidate inclisiran and is celebrating new safety data that raises the chances of approval when pivotal tria
